1060EGP
- Active ingredient
- budesonide+glycopyrronium+formoterol fumarate
- Strength
- 160/9/4.8 mcg
- Form
- spray
- Manufacturer
- astrazeneca
- Route
- mouth
Uses
Maintenance treatment of chronic obstructive pulmonary disease (COPD) in appropriate patients.
Do not use if
Hypersensitivity to any component.
Side effects
Oral candidiasis, cough, dry mouth, headache, and upper respiratory infections may occur.
Warnings
Not intended for acute bronchospasm relief. Rinse mouth after inhalation to reduce oral candidiasis risk.
How it works
Combines an inhaled corticosteroid, a long-acting beta2-agonist, and a long-acting muscarinic antagonist.
Storage
Store according to manufacturer recommendations and protect from excessive heat.